Labcorp (LH) Proxy filing summary

Executive summary

• Achieved $14.0B in 2025 revenues, up from $13.0B in 2024, with diluted EPS of $10.46 and adjusted EPS of $16.44, reflecting strong operational and financial performance.

• Launched over 130 new tests in high-growth areas and signed or closed 13 transactions, expanding partnerships with health systems and laboratories.

• Nearly 71,000 employees contributed to global operations, with over 175M patient interactions and services in 100+ countries.

• Strategic priorities included specialty testing, AI-enabled solutions, and global expansion, with a focus on oncology, neurology, autoimmune disease, and women's health.

Voting matters and shareholder proposals

• Shareholders will vote to elect eleven directors, approve executive compensation (say-on-pay), and ratify Deloitte & Touche LLP as the independent auditor for 2026.

• Board recommends a vote FOR all proposals.

• Shareholder engagement included discussions on strategy, ESG, executive compensation, and risk management.

Board of directors and corporate governance

• Ten of eleven director nominees are independent; board diversity is 64% (gender/ethnic/racial).

• Board refreshment included two new directors in 2025 and 2026, and new committee chairs.

• Lead Independent Director role is robust, with clear responsibilities for oversight and engagement.

• Board committees (Audit, Compensation and Human Capital, Nominating and Corporate Governance, Quality and Compliance) are fully independent and oversee key risk and governance areas.